A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

Abstract

This study provides Class II evidence that for patients with AD resveratrol is safe, well-tolerated, and alters some AD biomarker trajectories. The study is rated Class II because more than 2 primary outcomes were designated.